National Health (Immunisation Program—Designated Vaccines) Determination 2026

I, Jason Clare, Minister for Education, make the following determination.

Dated 29 September 2026

Jason Clare
Minister for Education
for the Minister for Health and Ageing

OPC67813 - B

Authorised Version F2026L01333 registered 30/09/2026

Authorised Version F2026L01333 registered 30/09/2026

Contents

Part 1—Preliminary 1

1 Name 1
2 Commencement....1
3 Authority 1
4 Schedule 2 1
5 Definitions....1
6 Meaning of *medical risk condition*....2

Part 2—Designated vaccines and circumstances 3

Division 1—Designated vaccines 3

7 Designated vaccines 3

Division 2—Circumstances 4

8 Circumstances 4
9 Catch-up doses for persons less than 10 years old....4
10 Catch-up doses for persons at least 10 years but less than 20 years old 4
11 Catch-up doses for visa-holders at least 20 years old 4

Schedule 1—Designated vaccines and circumstances 6

Part 1—Bacterial vaccines 6

1 Bacterial vaccines and circumstances 6

Part 2—Viral vaccines 22

2 Viral vaccines and circumstances 22

Part 3—Combined bacterial and viral vaccines 50

3 Combined bacterial and viral vaccines and circumstances 50

Schedule 2—Repeals 55

National Health (Immunisation Program — Designated Vaccines) Determination 2014 (No.1) 55

Authorised Version F2026L01333 registered 30/09/2026

Authorised Version F2026L01333 registered 30/09/2026

Part 1—Preliminary

1 Name

This instrument is the *National Health (Immunisation Program—Designated Vaccines) Determination 2026*.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	**Column 2**	**Column 3**
Provisions	**Commencement**	**Date/Details**
1. The whole of this instrument	1 October 2026.	1 October 2026

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsections 9B(2) and (5) of the *National Health Act 1953*.

4 Schedule 2

Each instrument that is specified in Schedule 2 to this instrument is amended or repealed as set out in the applicable items in that Schedule, and any other item in that Schedule has effect according to its terms.

5 Definitions

In this instrument:

µg means microgram.

Aboriginal person means a person of the Aboriginal race of Australia.

Act means the *National Health Act 1953*.

$CCID_{50}$ means cell culture infectious dose 50%, being the quantity of an infectious agent that when inoculated onto a number of susceptible cell cultures will infect 50% of the individual cultures.

Authorised Version F2026L01333 registered 30/09/2026

FHA means filamentous haemagglutinin.

FIM 2+3 means fimbrial agglutinogens 2+3.

IU means International Unit.

medical risk condition: see section 6.

PFU means plaque forming units.

PRN means pertactin.

PT means pertussis toxoid.

severe immunocompromise means a severely immunocompromising condition as described in the chapter titled *COVID-19* in the Australian Immunisation Handbook, published by the Department, as existing on 1 October 2026.

Note: The Australian Immunisation Handbook could in 2026 be viewed on the Department's Immunisation Handbook website (https://immunisationhandbook.health.gov.au).

table item, in relation to Schedule 1, means an item of a table in a clause in Schedule 1.

$TCID_{50}$ means tissue culture infectious dose 50%, being the quantity of an infectious agent that when inoculated onto a number of susceptible tissue cultures will infect 50% of the individual cultures.

Torres Strait Islander means a descendant of an Indigenous inhabitant of the Torres Strait Islands.

6 Meaning of *medical risk condition*

A ***medical risk condition*** is any of the following:

(a) functional or anatomical asplenia, including sickle cell disease, other haemoglobinopathies, congenital or acquired asplenia (e.g. splenectomy) or hyposplenia;

(b) immunocompromising conditions, including congenital or acquired immune deficiency including symptomatic IgG subclass or isolated IgA deficiency, haematological malignancies, solid organ transplant, haematopoietic stem cell transplant or HIV infection;

(c) chronic respiratory disease, including suppurative lung disease, bronchiectasis and cystic fibrosis or chronic lung disease of prematurity;

(d) chronic renal disease, including end stage renal disease (eGFR <15mL/min) or relapsing or persistent nephrotic syndrome;

(e) proven or presumptive cerebrospinal fluid leak;

(f) cochlear implants;

(g) intracranial shunts;

(h) previous episode of invasive pneumococcal disease;

(i) born less than 28 weeks gestation;

(j) trisomy 21;

(k) chronic heart disease, including cyanotic heart disease or heart failure.

Authorised Version F2026L01333 registered 30/09/2026

Part 2—Designated vaccines and circumstances

Division 1—Designated vaccines

7 Designated vaccines

For the purposes of subsection 9B(2) of the Act, a vaccine specified in Schedule 1 is determined to be a designated vaccine for the purposes of the Act.

Authorised Version F2026L01333 registered 30/09/2026

Division 2—Circumstances

8 Circumstances

For the purposes of subsection 9B(5) of the Act, the circumstances in which a designated vaccine may be provided are those specified for the vaccine in:

(a) Schedule 1; or

(b) another section of this Division.

9 Catch-up doses for persons less than 10 years old

A circumstance for a designated vaccine is that:

(a) the table item in Schedule 1 that specifies the vaccine specifies circumstances in which the vaccine may be provided to a person specified in those circumstances to be an age that is no more than 4 years; and

(b) the person did not receive the vaccine at the specified age; and

(c) the person is less than 10 years old.

Example: A vaccine is intended to be provided for the immunisation of a person at 2 months, 4 months and 6 months old but the person does not receive the vaccine at those ages, the doses of vaccine may be provided at any time before the person turns 10 years old.

10 Catch-up doses for persons at least 10 years but less than 20 years old

A circumstance for a designated vaccine is that:

(a) the vaccine is specified in table item 101, 102, 106, 202, 219, 220, 221, 222, 223, 225 or 226 in Schedule 1; and

(b) the table item specifies circumstances in which the vaccine may be provided to a person specified in those circumstances to be a certain age; and

(c) the person did not receive the vaccine at the specified age nor in accordance with the circumstance specified in section 9; and

(d) the person is at least 10 years old but less than 20 years old.

Note: The designated vaccines covered by paragraph (a) are Boostrix, Adacel, Nimenrix, H-B-Vax II, M-M-R II, Priorix, Priorix-Tetra, ProQuad, IPOL, Varilrix and Varivax Refrigerated.

11 Catch-up doses for visa-holders at least 20 years old

A circumstance for a designated vaccine is that:

(a) the vaccine is specified in table item 101, 102, 202, 219, 220, 223, 225 or 226 in Schedule 1; and

(b) the table item specifies circumstances in which the vaccine may be provided to a person specified in those circumstances to be a certain age; and

(c) the person did not receive the vaccine at the specified age nor in accordance with the circumstance specified in section 9 or 10; and

(d) the person is at least 20 years old; and

Authorised Version F2026L01333 registered 30/09/2026

(e) the person holds any of the following visas granted under the *Migration Act 1958*:

(i) Subclass 200 (Refugee) visa;

(ii) Subclass 201 (In-country Special Humanitarian) visa;

(iii) Subclass 202 (Global Special Humanitarian) visa;

(iv) Subclass 203 (Emergency Rescue) visa;

(v) Subclass 204 (Woman at Risk) visa.

Note: The designated vaccines covered by paragraph (a) are Boostrix, Adacel, H-B-Vax II, M-M-R II, Priorix, IPOL, Varilrix and Varivax Refrigerated.

Authorised Version F2026L01333 registered 30/09/2026

Section 1

Schedule 1—Designated vaccines and circumstances

Note: See sections 7 and 8.

Part 1—Bacterial vaccines

1 Bacterial vaccines and circumstances

Each item of the following table specifies:

(a) a bacterial vaccine; and

(b) circumstances in which the vaccine may be provided.

Note: Sections 9, 10 and 11 also specify circumstances in which certain vaccines may be provided.

Bacterial vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
101	Diphtheria, tetanus and pertussis (adult/adolescent)	Boostrix	Injection (0.5mL)	Each of the following: (a) diphtheria toxoid—not less than 2IU; (b) tetanus toxoid—not less than 20IU; (c) PT—8µg; (d) FHA—8µg; (e) PRN—2.5µg	One dose (booster)	Vaccine is provided to: (a) a person who is at least 10 years but less than 18 years old; or (b) a person who is pregnant.
102	Diphtheria, tetanus and pertussis (adult/adolescent)	Adacel	Injection (0.5mL)	Each of the following: (a) diphtheria toxoid—not less than 2IU;	One dose (booster)	Vaccine is provided to: (a) a person who is at least 10 years but less than 18 years old; or

Authorised Version F2026L01333 registered 30/09/2026

Bacterial vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
				(b) tetanus toxoid—not less than 20IU; (c) PT—2.5µg; (d) FHA—5µg; (e) PRN—3µg; (f) FIM 2+3—5µg		(b) a person who is pregnant.
103	Diphtheria, tetanus and pertussis (child)	Infanrix	Injection (0.5mL)	Each of the following: (a) diphtheria toxoid—not less than 30IU; (b) tetanus toxoid—not less than 40IU; (c) PT—25µg; (d) FHA—25µg; (e) PRN—8µg	One dose (booster)	Vaccine is provided to a person who is about 18 months old.
104	Diphtheria, tetanus and pertussis (child)	Tripacel	Injection (0.5mL)	Each of the following: (a) diphtheria toxoid—not less than 30IU; (b) tetanus toxoid—not less than 40IU; (c) PT—10µg; (d) FHA—5µg; (e) PRN—3µg; (f) FIM 2+3—5µg	One dose (booster)	Vaccine is provided to a person who is about 18 months old.
105	*Haemophilus*	ActHib or	Refrigerated	Purified Hib capsular	One dose (booster)	Vaccine is provided to:

Authorised Version F2026L01333 registered 30/09/2026

Section 1

Bacterial vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
	influenzae type b (Hib) (monovalent PRP-T)	Hiberix	lyophilised preparation for injection (0.5mL) with separate diluent	polysaccharide conjugated to tetanus toxoid—10µg		(a) a person who is about 18 months old; or (b) a person who: (i) is at least 5 years old; and (ii) has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; and (iii) did not receive childhood vaccinations; or (c) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan).
106	Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate	Nimenrix	Injection (0.5mL)	After reconstitution, each of the following: (a) Meningococcal polysaccharide - Serogroup A—5µg; (b) Meningococcal polysaccharide - Serogroup C—5µg; (c) Meningococcal polysaccharide - Serogroup W-135—5 µg; (d) Meningococcal polysaccharide - Serogroup Y—5µg.	As follows: (a) in the circumstances specified in paragraph (a), (b) or (f) of column 6—one dose; (b) primary doses in the circumstances specified in paragraph (c), (d) or (e) of column 6: (i) if at least 6 weeks but less than 6 months old at the start of the vaccine course–4 doses;	Vaccine is provided to: (a) a person who is 12 months old; or (b) a person who is at least 14 years but less than 20 years old; or (c) a person who has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; or (d) a person who has complement deficiency; or (e) a person who is undergoing treatment, or will commence treatment, with Soliris (eculizumab); or (f) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan).

Authorised Version F2026L01333 registered 30/09/2026

Bacterial vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
				Each dose contains conjugated to tetanus toxoid carrier protein 44μg	or (ii) if at least 6 months but less than 12 months old at the start of the vaccine course–3 doses; or (iii) if at least 12 months old at the start of the vaccine course–2 doses; (c) booster doses in the circumstances specified in paragraph (c), (d) or (e) of column 6: (i) if less than 7 years old when primary doses completed—1 booster dose 3 years after completing primary doses, and 1 booster dose every 5 years after that;	

Authorised Version F2026L01333 registered 30/09/2026

Section 1

Bacterial vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
					or (ii) if at least 7 years old when primary doses completed—1 booster dose every 5 years after completing primary doses	
107	Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine (Men ACWY-CRM)	Menveo	Injection (0.5mL)	Each of the following: (a) 10µg Meningococcal polysaccharide serogroup A conjugated to 16.7—33.3µg *Corynebacterium diphtheriae* CRM197 protein; (b) 5µg Meningococcal polysaccharide serogroup C conjugated to 7.1—12.5µg C. *diphtheriae* CRM197 protein; (c) 5µg Meningococcal	One dose	Vaccine is provided to: (a) a person who is at least 14 years but less than 17 years old as part of a school based program; or (b) a person who is at least 14 years but less than 19 years old who did not receive the vaccination as part of a school based program; or (c) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan).

Authorised Version F2026L01333 registered 30/09/2026

Bacterial vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
				polysaccharide serogroup W-135 conjugated to 3.3—8.3µg C. *diphtheriae* CRM197 protein; (d) 5µg Meningococcal polysaccharide serogroup Y conjugated to 5.6—10µg C. *diphtheriae* CRM197 protein		
108	Meningococcal *Neisseria meningitidis*, Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate serogroups A, C, W and Y	MenQuadfi	Injection (0.5mL)	Each of the following: (a) Meningococcal polysaccharide group A—10.0µg; (b) Meningococcal polysaccharide group C—10.0µg; (c) Meningococcal polysaccharide group Y—10.0µg; (d) Meningococcal polysaccharide group W-135—10.0µg.	As follows: (a) in the circumstances specified in paragraph (a) or (b) of column 6—one dose; (b) in the circumstances specified in paragraph (c), (d) or (e) of column 6: (i) primary doses—2 doses; and (ii) booster doses if less than 7 years old when	Vaccine is provided to: (a) a person who is 12 months old; or (b) a person who is at least 14 years but less than 20 years old; or (c) a person who is at least 12 months old and has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; or (d) a person who is at least 12 months old and has complement deficiency; or (e) a person who is at least 12 months old and is undergoing treatment, or will commence treatment, with Soliris (eculizumab); or (f) a person who is undergoing treatment,

Authorised Version F2026L01333 registered 30/09/2026

Section 1

Bacterial vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
				Each of the 4 polysaccharides is conjugated to tetanus toxoid (approximately 55µg/dose)	primary doses completed—1 booster dose 3 years after completing primary doses, and 1 booster dose every 5 years after that; and (iii) booster doses if at least 7 years old when primary doses completed—1 booster dose every 5 years after completing primary doses; (c) in the circumstances specified in paragraph (f) of column 6: (i) one dose; and (ii) booster doses—one dose every 5 years after that	or will commence treatment, with Empavali (pegcetacoplan).
109	Pneumococcal	Prevenar 13	Injection (0.5mL)	Polysaccharides of	As follows:	Vaccine is provided to:

Authorised Version F2026L01333 registered 30/09/2026

Bacterial vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
	(conjugate, 13 valent)			*Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F—4.4µg of serotype 6B and 2.2µg of each other serotype	(a) maximum of 3 primary doses in the circumstances specified in paragraph (a) of column 6, as follows: (i) one dose given at about 2 months old; (ii) one dose given at about 4 months old; (iii) one dose given at about 12 months but less than 24 months old; (b) in the circumstances specified in paragraph (c) of column 6—one dose; (c) booster dose in the circumstances specified in paragraph (b), (d), (e), (f), (g) or (h) of column 6—one dose	(a) a person who is about: (i) 2 months old; or (ii) 4 months old; or (iii) 12 months but less than 24 months old; or (b) a person who: (i) is about 6 months old; and (ii) lives in Queensland, Western Australia, South Australia or the Northern Territory; and (iii) is an Aboriginal person or Torres Strait Islander; or (c) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal haemoglobinuria who have an inadequate clinical response or are intolerant to treatment with eculizumab or ravulizumab; or (d) a person who is about 6 months old and has at least one medical risk condition; or (e) a person who is at least 12 months but less than 5 years old and has been newly diagnosed with at least one medical risk condition; or (f) a person who is at least 5 years old and

Authorised Version F2026L01333 registered 30/09/2026

Section 1

Bacterial vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
						has been newly diagnosed with at least one of the medical risk conditions mentioned in paragraphs 6(a) to (h); or (g) a person who is at least 50 years old and is an Aboriginal person or Torres Strait Islander; or (h) a person who is at least 70 years old.
110	Pneumococcal (conjugate, 20-valent)	Prevenar 20	Injection (0.5mL)	Polysaccharides of the capsular antigens of *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F individually conjugated to *Corynebacterium diphtheriae* CRM197 protein	Maximum of 3 doses, as follows: (a) one dose given at about 2 months old; (b) one dose given at about 4 months old; (c) one dose given at about 12 months but less than 24 months old	Vaccine is provided to a person who is: (a) about 2 months old; or (b) about 4 months old; or (c) about 12 months old but less than 24 months old
111	Pneumococcal (conjugate, 20-valent)	Prevenar 20	Injection (0.5mL)	Polysaccharides of the capsular antigens of *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F	Maximum of one dose	Vaccine is provided to: (a) a person who is about 6 months old and: (i) is an Aboriginal person or Torres Strait Islander; or (ii) has at least one medical risk condition; or

Authorised Version F2026L01333 registered 30/09/2026

Bacterial vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
				individually conjugated to *Corynebacterium diphtheriae* CRM197 protein		(b) a person who: (i) is at least 12 months but less than 5 years old; and (ii) has been newly diagnosed with at least one medical risk condition; or (c) a person who: (i) is at least 5 years but less than 18 years old; and (ii) has been newly diagnosed with at least one of the medical risk conditions mentioned in paragraphs 6(a) to (h).
112	Pneumococcal (conjugate, 21 valent)	Capvaxive	Injection (0.5mL)	84µg of pneumococcal purified capsular polysaccharide antigen (4µg each of polysaccharide serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, deOAc15B, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) conjugated to approximately 65µg of diphtheria *Corynebacterium*	Maximum of one dose	Vaccine is provided to: (a) a person who is at least 18 years old and has been diagnosed with: (i) at least one of the medical risk conditions mentioned in paragraphs 6(a) to (h); or (ii) chronic liver disease; or (iii) chronic obstructive pulmonary disease; or (b) a person who: (i) is at least 25 years old; and (ii) is an Aboriginal person or Torres Strait Islander; or (c) a person who is at least 65 years old; or

Authorised Version F2026L01333 registered 30/09/2026

Section 1

Bacterial vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
				diphtheriae CRM197 protein		(d) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan).
113	Pneumococcal (polysaccharide, 23-valent)	PneumoVax 23	Injection (0.5mL)	Polysaccharides of *Streptococcus pneumoniae* serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F—25µg of each serotype	As follows: (a) in the circumstances specified in paragraph (a) of column 6—2 doses; (b) in the circumstances specified in paragraph (b), (c), (d) or (e) of column 6: (i) first dose—one dose; and (ii) second dose—one dose given at least 5 years after the first dose	Vaccine is provided to: (a) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal haemoglobinuria who have an inadequate clinical response or are intolerant to treatment with eculizumab or ravulizumab; or (b) a person who: (i) is at least 4 years but less than 6 years old; and (ii) has at least one medical risk condition; or (c) a person who: (i) is at least 5 years old; and (ii) has been newly diagnosed with at least one of the medical risk conditions mentioned in paragraphs 6(a) to (h); or (d) a person who: (i) is at least 4 years but less than 6 years old; and (ii) lives in Queensland, Western

Authorised Version F2026L01333 registered 30/09/2026

Bacterial vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
						Australia, South Australia or the Northern Territory; and (iii) is an Aboriginal person or Torres Strait Islander; or (e) a person who: (i) is at least 50 years old; and (ii) is an Aboriginal person or Torres Strait Islander; and (iii) has not received a dose under paragraph (c).
114	Multicomponent meningococcal group B (4CMenB)	Bexsero	Injection (0.5mL)	Each of the following: (a) *Neisseria meningitidis* serogroup B Neisseria heparin binding antigen fusion protein—50µg; (b) *Neisseria meningitidis* serogroup B Neisseria adhesion A protein—50µg; (c) *Neisseria meningitidis* serogroup B factor H binding protein fusion protein—	As follows: (a) in the circumstances specified in paragraph (a) of column 6—2 doses provided at least 8 weeks apart; (b) in the circumstances specified in paragraph (c) of column 6—as follows: (i) if at least 2 months old at the start of the vaccine course—3 primary doses at least 8 weeks	Vaccine is provided to: (a) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan); or (b) a person who is undergoing treatment, or will commence treatment, with Soliris (eculizumab); or (c) a person who is an Aboriginal person or Torres Strait Islander, and has any of the following medical conditions known to increase the risk of invasive meningococcal disease: (i) defects in, or deficiency of, complement components, including factor H, factor D or properdin deficiency; (ii) current or future treatment with eculizumab (a monoclonal

Authorised Version F2026L01333 registered 30/09/2026

Section 1

Bacterial vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
				50µg; (d) outer membrane vesicles from *Neisseria meningitidis* serogroup B strain NZ98/254 (measured as amount of total protein containing the PorA P1.4)—25µg	apart, and one booster dose when at least 12 months old; (ii) if less than 2 years old at the start of the vaccine course—3 primary doses at least 8 weeks apart, and one booster dose given at least 6 months after completing primary doses; (c) in the circumstances specified in paragraph (d) of column 6—as follows: (i) if at least 2 months old at the start of the vaccine course—2 primary doses at least 8 weeks	antibody directed against complement component C5); (iii) functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies, and congenital or acquired asplenia; (iv) HIV, regardless of disease stage or CD4+ cell count; (v) haematopoietic stem cell transplant; or (d) a person who: (i) is an Aboriginal person or Torres Strait Islander; and (ii) is not covered by paragraph (c); or (e) a person who has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; or (f) a person who has complement deficiency.

Authorised Version F2026L01333 registered 30/09/2026

Bacterial vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
					apart, and one booster dose when at least 12 months old; (ii) if less than 2 years old at the start of the vaccine course and has not received a dose under subparagraph (i)—2 primary doses at least 8 weeks apart, and one booster dose given at least 8 months after completing primary doses; (d) in the circumstances specified in paragraph (b), (e) or (f) of column 6—as follows: (i) if at least 6 weeks but less than 6 months	

Section 1

Bacterial vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
					old at the start of the vaccine course—3 primary doses at least 8 weeks apart, and one booster dose when at least 12 months old; (ii) if at least 6 months but less than 12 months old at the start of the vaccine course—2 primary doses at least 8 weeks apart, and one booster dose when at least 12 months old; (iii) if at least 12 months old at the start of the vaccine course—2 primary doses at least 8 weeks	

Authorised Version F2026L01333 registered 30/09/2026

Section 1

Bacterial vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
					apart	

Section 2

Part 2—Viral vaccines

2 Viral vaccines and circumstances

Each item of the following table specifies:

(a) a viral vaccine; and

(b) circumstances in which the vaccine may be provided.

Note: Sections 9, 10 and 11 also specify circumstances in which certain vaccines may be provided.

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
201	Hepatitis A (monovalent)	VAQTA Paediatric/ Adolescent	Injection (0.5mL)	Hepatitis A virus protein—25 units	2 doses given 6 months apart	Vaccine is provided to a person who: (a) is an Aboriginal person or Torres Strait Islander; and (b) is at least 1 year but less than 5 years old; and (c) lives in Queensland, Western Australia, South Australia or the Northern Territory.
202	Hepatitis B (monovalent adult)	H-B-Vax II	Vial for injection (1mL)	Hepatitis B surface antigen protein—10µg	2 doses given between 4 and 6 months apart	Vaccine is provided to a person who is at least 10 years but less than 14 years old.
203	Hepatitis B (monovalent paediatric)	Engerix-B	Vial for injection (0.5mL)	Hepatitis B surface antigen protein—10µg	As follows: (a) in the circumstances specified in	Vaccine is provided to: (a) a newborn infant as soon as practicable after birth but no later than 7 days after

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
					paragraph (a) of column 6—one dose; (b) in the circumstances specified in paragraph (b) of column 6: (i) first dose—one dose; and (ii) second dose—one dose given 1 month after the first dose; and (iii) third dose—one dose given 5 months after the second dose	birth; or (b) a person who: (i) is at least 10 years but less than 14 years old; and (ii) has not received a Hepatitis B containing vaccine.
204	Hepatitis B (monovalent paediatric)	H-B-Vax II	Vial for injection (0.5mL)	Hepatitis B surface antigen protein—5µg	One dose	Vaccine is provided to a newborn infant as soon as practicable after birth but no later than 7 days after birth.
205	Influenza	Influvac or Fluarix	Injection (0.5mL)		As follows: (a) for a person who is at least 6 months but less than 9 years old: (i) 2 doses at least 1 month apart; and (ii) one dose in each subsequent calendar year;	Vaccine is provided to a person who: (a) is at least 65 years; or (b) is: (i) an Aboriginal person or Torres Strait Islander; and (ii) at least 6 months but less than 5 years old, or at least 15 years old; or

Authorised Version F2026L01333 registered 30/09/2026

Section 2

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
					(b) for a person who is at least 9 years old—one dose per calendar year. For persons who are at least 6 months but less than 3 years old, the dose is 0.25mL	(c) is at least 6 months old and has any of the following: (i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure; (ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma; (iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment); (iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders;

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
						(v) impaired immunity, including HIV infection; or (d) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or (e) is pregnant.
206	Influenza	Fluarix Tetra	Injection (0.5mL)		As follows: (a) for a person who is at least 6 months but less than 9 years old: (i) 2 doses at least 1 month apart; and (ii) one dose in each subsequent calendar year; (b) for a person who is at least 9 years old—one dose per calendar year.	Vaccine is provided to a person who: (a) is at least 65 years; or (b) is an Aboriginal person or Torres Strait Islander and is at least 6 months old; or (c) is at least 6 months but less than 5 years old; or (d) is at least 6 months old and has any of the following: (i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure; (ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma; (iii) another chronic illness requiring regular medical follow-up or hospitalisation in

Section 2

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
						the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment); (iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; (v) impaired immunity, including HIV infection; or (e) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or (f) is pregnant.
207	Influenza	FluQuadri	Injection (0.5mL)		As follows: (a) for a person who is at least 6 months but less than 9 years old: (i) 2 doses at least 1 month apart; and (ii) one dose in each subsequent calendar year;	Vaccine is provided to a person who: (a) is at least 65 years; or (b) is an Aboriginal person or Torres Strait Islander and is at least 6 months old; or (c) is at least 6 months but less than 5 years old; or (d) is at least 6 months old and has any of the following:

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
					(b) for a person who is at least 9 years old—one dose per calendar year.	(i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure; (ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma; (iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment); (iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; (v) impaired immunity, including HIV infection; or

Section 2

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
						(e) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or (f) is pregnant.
208	Influenza	Afluria Quad	Injection (0.5mL)		One dose per calendar year	Vaccine is provided to a person who: (a) is at least 65 years; or (b) is an Aboriginal person or Torres Strait Islander and is at least 5 years old; or (c) is at least 5 years old and has any of the following: (i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure; (ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma; (iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure,

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
						haemoglobinopathies or impaired immunity (including drug-induced immune impairment); (iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; (v) impaired immunity, including HIV infection; or (d) is pregnant.
209	Influenza	Fluzone High Dose	Injection (0.5mL)		One dose per calendar year	Vaccine is provided to a person who is at least 65 years old.
210	Influenza	Fluad	Injection (0.5mL)		One dose per calendar year	Vaccine is provided to a person who is at least 65 years old.
211	Influenza	VaxiGrip Tetra	Injection (0.5mL)		As follows: (a) for a person who is at least 6 months but less than 9 years old: (i) 2 doses at least 1 month apart; and (ii) one dose in each subsequent calendar year; (b) for a person who is at least 9 years old—one	Vaccine is provided to a person who: (a) is at least 65 years; or (b) is an Aboriginal person or Torres Strait Islander and is at least 6 months old; or (c) is at least 6 months but less than 5 years old; or (d) is at least 6 months old and has any of the following: (i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease

Section 2

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
					dose per calendar year.	or congestive heart failure; (ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma; (iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment); (iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; (v) impaired immunity, including HIV infection; or (e) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
						(f) is pregnant.
212	Influenza	Fluad Quad	Injection (0.5mL)		One dose per calendar year	Vaccine is provided to a person who is at least 65 years old.
213	Influenza	FluQuadri Junior	Injection (0.25mL)		As follows: (a) 2 doses at least 1 month apart; (b) one dose in each subsequent calendar year	Vaccine is provided to a person who: (a) is at least 6 months but less than 3 years old; and (b) is an Aboriginal person or Torres Strait Islander, or: (i) has cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure; or (ii) has a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma; or (iii) has another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or

Section 2

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
						impaired immunity (including drug-induced immune impairment); or (iv) has a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; or (v) has impaired immunity, including HIV infection; or (vi) is receiving long-term aspirin therapy.
214	Influenza	Flucelvax Quad	Injection (0.5mL)		As follows: (a) for a person who is at least 6 months but less than 9 years old: (i) 2 doses at least 1 month apart; and (ii) one dose in each subsequent calendar year; (b) for a person who is at least 9 years but less than 65 years old—one dose per calendar year.	Vaccine is provided to a person who: (a) is at least 6 months but less than 5 years old; or (b) is an Aboriginal person or Torres Strait Islander and is at least 6 months but less than 65 years old; or (c) is at least 6 months but less than 65 years old and has any of the following: (i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure; (ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
						pulmonary disease, chronic emphysema or severe asthma; (iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment); (iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; (v) impaired immunity, including HIV infection; or (d) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or (e) is pregnant.
215	Influenza	Vaxigrip	Injection (0.5mL)		As follows: (a) for a person who is at least 6 months but less than 9 years old:	Vaccine is provided to a person who: (a) is at least 65 years; or (b) is an Aboriginal person or Torres Strait

Authorised Version F2026L01333 registered 30/09/2026

Section 2

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
					(i) 2 doses at least 1 month apart; and (ii) one dose in each subsequent calendar year; (b) for a person who is at least 9 years old—one dose per calendar year.	Islander and is at least 6 months old; or (c) is at least 6 months but less than 5 years old; or (d) is at least 6 months old and has any of the following: (i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure; (ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma; (iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment); (iv) a chronic neurological condition, including multiple

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
						sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; (v) impaired immunity, including HIV infection; or (e) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or (f) is pregnant.
216	Influenza	Fluzone	Injection (0.5mL)		As follows: (a) for a person who is at least 6 months but less than 9 years old: (i) 2 doses at least 1 month apart; and (ii) one dose in each subsequent calendar year; (b) for a person who is at least 9 years old—one dose per calendar year.	Vaccine is provided to a person who: (a) is at least 65 years; or (b) is an Aboriginal person or Torres Strait Islander and is at least 6 months old; or (c) is at least 6 months but less than 5 years old; or (d) is at least 6 months old and has any of the following: (i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure; (ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma;

Section 2

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
						(iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment); (iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; (v) impaired immunity, including HIV infection; or (e) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or (f) is pregnant.
217	Influenza	Flucelvax	Injection (0.5mL)		As follows: (a) for a person who is at least 6 months but less than 9 years old: (i) 2 doses at least 1 month apart; and	Vaccine is provided to a person who: (a) is at least 6 months but less than 5 years old; or (b) is an Aboriginal person or Torres Strait Islander and is at least 6 months but less than 65 years old; or

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
					(ii) one dose in each subsequent calendar year; (b) for a person who is at least 9 years but less than 65 years old—one dose per calendar year.	(c) is at least 6 months but less than 65 years old and has any of the following: (i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure; (ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma; (iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment); (iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders;

Section 2

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
						(v) impaired immunity, including HIV infection; or (d) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or (e) is pregnant.
218	Influenza	Flublok	Injection (0.5mL)		One dose per calendar year.	Vaccine is provided to a person who is at least 65 years old.
219	Measles, mumps and rubella	M-M-R II	Refrigerated lyophilised preparation for injection (0.5mL)	Each of the following live attenuated viruses: (a) measles virus (Edmonston strain)—1000 $TCID_{50}$; (b) mumps virus (Jeryl Lynn strain)—5000 $TCID_{50}$; (c) rubella virus (Wistar RA 27/3 strain)—1000 $TCID_{50}$	As follows: (a) in the circumstances specified in paragraph (a) of column 6—one dose; (b) in the circumstances specified in paragraph (b) of column 6—one dose; (c) in the circumstances specified in paragraph (c) of column 6—one dose	Vaccine is provided to a person who is: (a) about 12 months old; or (b) about 18 months old if given concurrently with a monovalent varicella vaccine; or (c) about 4 years old if the person was not given either of the following at about 18 months old: (i) a dose in the circumstances specified in paragraph (b); (ii) a measles, mumps, rubella and varicella vaccine.
220	Measles, mumps and rubella	Priorix	Refrigerated lyophilised preparation for injection (0.5mL)	Each of the following live attenuated viruses: (a) measles virus (Schwarz strain)—$10^{3.0}$ $CCID_{50}$; (b) mumps virus (RIT	As follows: (a) in the circumstances specified in paragraph (a) of column 6—one dose; (b) in the circumstances	Vaccine is provided to a person who is: (a) about 12 months old; or (b) about 18 months old if given concurrently with a monovalent varicella vaccine; or

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
				4385 strain derived from the Jeryl Lynn strain)—$10^{3.7}$ $CCID_{50}$; (c) rubella virus (Wistar RA 27/3 strain)—$10^{3.0}$ $CCID_{50}$	specified in paragraph (b) of column 6—one dose; (c) in the circumstances specified in paragraph (c) of column 6—one dose	(c) about 4 years old if the person was not given either of the following at about 18 months old: (i) a dose in the circumstances specified in paragraph (b); (ii) a measles, mumps, rubella and varicella vaccine.
221	Measles, mumps, rubella and varicella	Priorix-Tetra	Powder for injection vial with diluent syringe (0.5mL)	Each of the following live attenuated viruses: (a) measles virus (Schwarz strain)—$10^{3.0}$ $CCID_{50}$; (b) mumps virus (RIT 4385 strain derived from Jeryl Lynn strain)—$10^{4.4}$ $CCID_{50}$; (c) rubella virus (Wistar RA 27/3 strain)—$10^{3.0}$ $CCID_{50}$; (d) varicella virus (Oka strain)—$10^{3.3}$ PFU	One dose	Vaccine is provided to a person who is about 18 months old.
222	Measles, mumps, rubella and varicella	ProQuad	Injection (0.5mL)	Each of the following live attenuated viruses: (a) measles virus	One dose	Vaccine is provided to a person who is about 18 months old.

Section 2

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
				derived from Enders' attenuated Edmonston strain—$10^{3.0}$ $TCID_{50}$; (b) mumps virus (Jeryl Lynn™ (B Level) strain)—$10^{4.3}$ $TCID_{50}$; (c) rubella virus (Wistar RA 27/3 strain)—$10^{3.0}$ $TCID_{50}$; (d) Varicella-zoster virus (Oka/Merck strain)—$10^{3.99}$ PFU		
223	Poliomyelitis	IPOL	Injection (0.5mL)	Each of the following killed whole polioviruses: (a) type 1 (Mahoney)—40 D-antigen units; (b) type 2 (MEF-1)—8 D-antigen units; (c) type 3 (Saukett)—32 D-antigen units	As follows: (a) at about 2 months old—one dose; (b) at about 4 months old—one dose; (c) at about 6 months old—one dose; (d) at about 4 years old—one dose	Vaccine is provided to a person: (a) who is about: (i) 2 months old; or (ii) 4 months old; or (iii) 6 months old; or (iv) 4 years old; and (b) if all other vaccines containing poliovirus are unsuitable.
224	BNT162b2	Comirnaty	Injection (0.3mL)	SARS-CoV-2 spike	As follows:	Vaccine is provided to:

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
	mRNA COVID-19			protein (mRNA)—30µg	(a) in the circumstances specified in paragraph (a), (b) or (c) of column 6—one dose per calendar year; (b) in the circumstances specified in paragraph (d) of column 6—2 doses per calendar year	(a) a person who: (i) is at least 18 years but less than 65 years old; and (ii) has a severe immunocompromise; or (b) a person who is at least 65 years but less than 75 years old; or (c) a person who: (i) is an Aboriginal person or Torres Strait Islander; and (ii) is at least 50 years but less than 75 years old; or (d) a person who is at least 75 years old.
225	Varicella	Varilrix	Refrigerated lyophilised preparation for injection (0.5mL)	Live attenuated Oka strain of the varicella-zoster virus—$10^{3.3}$ PFU	One dose	Vaccine is provided to a person who: (a) is about 18 months old; or (b) is at least 10 years but less than 14 years old, and has not had varicella nor been given a varicella vaccine.
226	Varicella	Varivax Refrigerated	Refrigerated lyophilised preparation for injection (0.5mL)	Live attenuated Oka/Merck strain of the varicella-zoster virus—at least 1350 PFU	One dose	Vaccine is provided to a person who: (a) is about 18 months old; or (b) is at least 10 years but less than 14 years old, and has not had varicella nor been given a varicella vaccine.
227	Herpes zoster (shingles)	Shingrix	Powder and suspension for injection (0.5mL)	Recombinant varicella zoster virus glycoprotein E antigen	As follows: (a) if a person is immunodeficient,	Vaccine is provided to a person who: (a) is at least 65 years old; or (b) is at least 50 years old and is an

Section 2

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
				(AS01B Adjuvanted)—50µg	immunosuppressed or likely to become immunosuppressed due to a known disease or therapy—2 primary doses given between 1 and 2 months apart; (b) otherwise—2 primary doses given between 2 and 6 months apart	Aboriginal person or Torres Strait Islander; or (c) is at least 18 years old and is considered at increased risk of herpes zoster due to an underlying condition, including any of the following: (i) acute haematological malignancies such as acute leukaemia or aggressive lymphomas; (ii) chronic haematological malignancies, such as the following: (A) myelodysplastic syndromes; (B) chronic myeloproliferative disorders; (C) lymphoproliferative malignancies; (D) plasma cell dyscrasias which includes myeloproliferative neoplasms, chronic lymphocytic leukaemia, indolent non-Hodgkin lymphoma or multiple myeloma; (iii) human immunodeficiency virus infection with CD4+ cell count <200/µL;

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
						(iv) inborn errors of immunity with ongoing functional deficits, including any of the following: (A) humoral e.g. X-linked agammaglobulinemia; (B) combined defects, such as severe combined immunodeficiency; (C) phagocytic disorders, such as chronic granulomatous disease; (D) other inborn errors of immunity except complement disorders, hereditary angioedema and IgA deficiency; (v) stage 5 kidney disease or on dialysis; or (d) is at least 18 years old and is considered at increased risk of herpes zoster due to malignancy, autoimmune or inflammatory conditions receiving immunomodulatory or immunosuppressive treatments, including any of the following: (i) cellular therapies, whether received currently or within the previous 24 months, including

Authorised Version F2026L01333 registered 30/09/2026

Section 2

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
						any of the following: (A) autologous haematopoietic stem cell transplant; (B) allogeneic haematopoietic stem cell transplant, including ongoing graft versus host disease with immunosuppressive therapy, where a person is considered high risk beyond a 24 month period; (C) chimeric antigen receptor T-cell therapy; (ii) B and T-cell targeted monoclonal antibody therapies, whether received currently or within the last 6 months, including any of the following: (A) anti-CD20; (B) anti B-cell activating factor; (C) anti-CD52; (D) anti-thymocyte globulin; (iii) conventional chemotherapy for: (A) treatment of haematological malignancy; or (B) solid organ tumours, whether received currently or within the last 6 months;

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
						(iv) immunosuppressive therapy to prevent organ rejection prior to or following solid organ transplantation, whether received currently or within the last 6 months; (v) conventional immunosuppressive agents, whether received currently or within the last 6 months, including any of the following: (A) high dose methotrexate ≥20mg per week (oral and subcutaneous); (B) azathioprine ≥3.0mg/kg/day; (C) 6-mercaptopurine ≥1.5mg/kg/day; (D) mycophenolate ≥1g/day; (E) cyclophosphamide; (F) systemic calcineurin inhibitors such as tacrolimus or cyclosporin; (G) mTOR inhibitors; (H) purine analogues, such as cladribine; (vi) biologic therapies, whether received currently or within the last 6 months, not including

Authorised Version F2026L01333 registered 30/09/2026

Section 2

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
						lower risk biologics such as anti-integrins including natalizumab and vedolizumab, anti-IgE antibodies, anti-complement antibodies and lower risk interleukin (IL) inhibitors, anti-IL17 antibodies, anti-IL12/23 antibodies, anti-IL23 antibodies, and anti-IL31 antibodies, but including any of the following: (A) tumour necrosis factor inhibitors; (B) T-cell co-stimulation modulators such as Abatacept; (C) soluble TNF receptors; (D) type I interferon receptor inhibitors; (E) proteasome inhibitors; (F) IL inhibitors, whether received currently or within the last 6 months, including anti-IL1 antibodies, anti-IL4/13 antibodies, anti-IL5 antibodies, anti-IL6 antibodies and IL-6 receptor inhibitors;

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
						(vii) immunomodulatory drugs, whether received currently or within the last 6 months, including sphingosine-1-phosphate receptor modulators; (viii) oral small molecule targeted therapies, whether received currently or within the last 6 months, including any of the following: (A) bruton's tyrosine kinase inhibitors; (B) janus kinase inhibitors; (C) BCR-ABL inhibitors.
228	Human papillomavirus (HPV) (9-valent)	Gardasil 9	Injection (0.5mL)	Each of the following: (a) HPV 6 L1 protein—30µg; (b) HPV 11 L1 protein—40µg; (c) HPV 16 L1 protein—60µg; (d) HPV 18 L1 protein—40µg; (e) HPV 31 L1 protein—20µg; (f) HPV 33 L1	As follows: (a) in the circumstances specified in paragraph (a) or (b) of column 6—one dose; (b) in the circumstances specified in paragraph (c) of column 6—3 doses given between 6 and 12 months apart	Vaccine is provided to a person who: (a) is at least 12 years but less than 14 years old; or (b) is at least 12 years but less than 26 years old and has not received a single dose of Human papillomavirus vaccine; or (c) is at least 12 years but less than 26 years old and has impaired immunity.

Authorised Version F2026L01333 registered 30/09/2026

Section 2

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
				protein—20µg; (g) HPV 45 L1 protein—20µg; (h) HPV 52 L1 protein—20µg; (i) HPV 58 L1 protein—20µg		
229	Rotavirus	Rotarix	Oral suspension (1.5mL) in oral applicator	Human rotavirus vaccine, live attenuated, RIX 4414 strain (G1P[8])—not less than 10^6 $CCID_{50}$	2 doses as follows: (a) first dose given between 6 and 14 weeks old; (b) second dose given between 14 and 24 weeks old	Vaccine is provided to a person who is about: (a) 2 months old; or (b) 4 months old.
230	Rotavirus	RotaTeq	Oral solution (2.0mL)	Live pentavalent reassortant vaccine containing each of the following: (a) G1—2.2 x 10^6 IU; (b) G2—2.8 x 10^6 IU; (c) G3—2.2 x 10^6 IU; (d) G4—2.0 x 10^6 IU; (e) P1 (8)—2.3 x 10^6 IU	3 doses as follows: (a) first dose given between 6 and 14 weeks old; (b) second dose given between 14 and 24 weeks old; (c) third dose given before 32 weeks old	Vaccine is provided to a person who is about: (a) 2 months old; or (b) 4 months old; or (c) 6 months old.
231	Respiratory syncytial virus (RSV) stabilised	Abrysvo	Injection (0.5mL)	stabilised prefusion F proteins (60µg RSV-A and 60µg RSV-B	One dose: (a) between 28 and 36 weeks gestation; or	Vaccine is provided to a person who is pregnant.

Authorised Version F2026L01333 registered 30/09/2026

Viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
	prefusion F subunit			antigens)—120µg	(b) after 36 weeks gestation if vaccination is 2 weeks prior to expected date of birth.	
232	Respiratory syncytial virus (RSV) stabilised prefusion F protein ($AS01_E$ adjuvanted)	Arexvy	Injection (0.5mL)	recombinant respiratory syncytial virus pre-fusion F protein (RSVPreF3) antigen adjuvanted with $AS01_E$—120µg	One dose	Vaccine is provided to a person who: (a) is at least 75 years old; or (b) is an Aboriginal person or Torres Strait Islander and is at least 60 years old.

Authorised Version F2026L01333 registered 30/09/2026

Part 3—Combined bacterial and viral vaccines

3 Combined bacterial and viral vaccines and circumstances

Each item of the following table specifies:

(a) a combined bacterial and viral vaccine; and

(b) circumstances in which the vaccine may be provided.

Note: Sections 9, 10 and 11 also specify circumstances in which certain vaccines may be provided.

Combined bacterial and viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
301	Diphtheria, tetanus, pertussis and poliomyelitis	Infanrix-IPV	Injection (0.5mL)	Each of the following: (a) diphtheria toxoid—not less than 30IU; (b) tetanus toxoid—not less than 40IU; (c) PT—25µg; (d) FHA—25µg; (e) PRN—8µg; (f) inactivated poliovirus type 1 (Mahoney)—40 D-antigen units; (g) inactivated poliovirus type 2 (MEF-1)—8 D-antigen units;	Maximum of 4 doses as follows: (a) one dose given at about 2 months old; (b) one dose given at about 4 months old; (c) one dose given at about 6 months old; (d) one dose given at the age described in paragraph (d) of column 6	Vaccine is provided to a person who is: (a) about 2 months old; or (b) about 4 months old; or (c) about 6 months old; or (d) at least 3 years and 6 months old and less than 5 years old.

Authorised Version F2026L01333 registered 30/09/2026

Combined bacterial and viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
				(h) inactivated poliovirus type 3 (Saukett)—32 D-antigen units		
302	Diphtheria, tetanus, pertussis and poliomyelitis	Quadracel	Vial for injection (0.5mL)	Each of the following: (a) diphtheria toxoid—not less than 30IU; (b) tetanus toxoid—not less than 40IU; (c) PT—20µg; (d) FHA—20µg; (e) PRN—3µg; (f) FIM 2+3—5µg; (g) inactivated poliovirus type 1 (Mahoney)—40 D-antigen units; (h) inactivated poliovirus type 2 (MEF-1)—8 D-antigen units; (i) inactivated poliovirus type 3 (Saukett)—32 D-antigen units	Maximum of 4 doses as follows: (a) one dose given at about 2 months old; (b) one dose given at about 4 months old; (c) one dose given at about 6 months old; (d) one dose given at the age described in paragraph (d) of column 6	Vaccine is provided to a person who is: (a) about 2 months old; or (b) about 4 months old; or (c) about 6 months old; or (d) at least 3 years and 6 months old and less than 5 years old.
303	Diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and *Haemophilus*	Infanrix-Hexa	Injection (0.5mL) combination pack	Each of the following: (a) diphtheria toxoid—not less than 30IU; (b) tetanus toxoid—not less than 40IU;	Maximum of 3 doses as follows: (a) one dose given at about 2 months old; (b) one dose given at	Vaccine is provided to a person who is: (a) about 2 months old; or (b) about 4 months old; or (c) about 6 months old.

Authorised Version F2026L01333 registered 30/09/2026

Section 3

Combined bacterial and viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
	influenzae type b (Hib)			(c) PT—25µg; (d) FHA—25µg; (e) PRN—8µg; (f) inactivated poliovirus type 1 (Mahoney)—40 D-antigen units; (g) inactivated poliovirus type 2 (MEF-1)—8 D-antigen units; (h) inactivated poliovirus type 3 (Saukett)—32 D-antigen units; (i) recombinant hepatitis B surface antigen—10µg; (j) purified Hib capsular polysaccharide conjugated to tetanus toxoid—10µg	about 4 months old; (c) one dose given at about 6 months old	
304	Diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and *Haemophilus influenzae* type b (Hib)	Hexaxim	Injection (0.5mL)	Each of the following: (a) diphtheria toxoid—not less than 20IU; (b) tetanus toxoid—not less than 40IU; (c) PT—25µg; (d) FHA—25µg;	Maximum of 3 doses as follows: (a) one dose given at about 2 months old; (b) one dose given at about 4 months old; (c) one dose given at	Vaccine is provided to a person who is: (a) about 2 months old; or (b) about 4 months old; or (c) about 6 months old.

Authorised Version F2026L01333 registered 30/09/2026

Combined bacterial and viral vaccines and circumstances

Item	Column 1 Disease	Column 2 Brand	Column 3 Formulation	Column 4 Active ingredient and strength	Column 5 Doses	Column 6 Circumstances
				(e) inactivated poliovirus type1 (Mahoney)—40 D-antigen units; (f) inactivated poliovirus type 2 (MEF-1)—8 D-antigen units; (g) inactivated poliovirus type 3 (Saukett)—32 D-antigen units; (h) recombinant hepatitis B surface antigen—10µg; (i) Hib polysaccharide (Polyribosylribitol Phosphate)—12µg; (j) Hib polysaccharide conjugated to tetanus protein—22-36µg	about 6 months old	
305	Diphtheria, tetanus, pertussis and poliomyelitis, hepatitis B, and *Haemophilus influenzae* type b (DTPa-HB-IPV-Hib)	Vaxelis	Injection (0.5mL)	Each of the following: (a) diphtheria toxoid—not less than 20IU; (b) tetanus toxoid—not less than 40IU; (c) PT—20µg; (d) FHA—20µg; (e) PRN—3µg;	Maximum of 3 doses as follows: (a) one dose given at about 2 months old; (b) one dose given at about 4 months old; (c) one dose given at about 6 months old	Vaccine is provided to a person who is: (a) about 2 months old, and not less than 6 weeks old; or (b) about 4 months old; or (c) about 6 months old.

Section 3

Combined bacterial and viral vaccines and circumstances						
Item	**Column 1** **Disease**	**Column 2** **Brand**	**Column 3** **Formulation**	**Column 4** **Active ingredient and strength**	**Column 5** **Doses**	**Column 6** **Circumstances**
				(f) FIM—3µg; (g) Hepatitis B surface antigen—10µg; (h) inactivated poliovirus type 1 (Mahoney)—40 D-antigen units; (i) inactivated poliovirus type 2 (MEF-1)—8 D-antigen units; (j) inactivated poliovirus type 3 (Saukett)—32 D-antigen units; (k) hepatitis B surface antigen—10µg; (l) *Haemophilus influenzae* type b polysaccharide (Polyribosylribitol Phosphate)—3µg; (m) Conjugated to meningococcal protein2—50µg		

Authorised Version F2026L01333 registered 30/09/2026

Schedule 2—Repeals

National Health (Immunisation Program — Designated Vaccines) Determination 2014 (No.1)

1 The whole of the instrument

Repeal the instrument.

Authorised Version F2026L01333 registered 30/09/2026